Advertisement

Use of USPIOs for Clinical Lymph Node Imaging

  • Jelle O. Barentsz
  • Paris P. Tekkis
Part of the Fundamental Biomedical Technologies book series (FBMT, volume 102)

Abstract

The detection of lymph node metastases is critical for the choice of preoperative chemo-radiotherapy, surgical treatment, and patient prognosis. Ultrasmall superparamagnetic iron oxide (USPIO) enhanced magnetic resonance imaging (MRI) is now being used as a potential biomarker for the detection of lymph node metastases. USPIO is transported into the interstitial space and reaches the lymph nodes via the lymphatic circulation acting as a ‘negative contrast’ agent, which can potentially identify metastases independent of lymph node size. We assessed here the diagnostic precision and application of magnetic resonance imaging (MRI) in conjunction with USPIO contrast as a biomarker for detecting LNMs pre-operatively, compared with the gold-standard post-operative histopathology. A total of 19 prospective studies have been published between 1994 and 2005, comprising 3,004 lymph nodes in 631 patients who underwent comparable MR imaging with and without USPIO. The overall sensitivity and specificity for MRI with USPIO were 88.1% and 96.2% respectively, with an area under the ROC curve of 84.2% and a diagnostic odds ratio of 123.1. When unenhanced MRI was evaluated, there was a significant reduction in the overall sensitivity and specificity (63% and 92.7% respectively) and a diagnostic odds ratio of 26.7. USPIO-enhanced MRI had a higher sensitivity and specificity for lymph node status in the abdomen and pelvis compared with the chest or head and neck. Similarly, the diagnostic precision was better when a 3T MRI scanner was used at 2.6 mg/kg contrast dose, than when using a 1.5T field strength. Thus, USPIO is a promising nanomarker, which may potentially increase the precision for the pre-operative diagnosis of lymph node metastases. It may be used for providing guidelines for selecting patients for targeted neo-adjuvant chemotherapy and extended lymphadenectomy thus possibly reducing the incidence of local recurrence.

Keywords

Lymph Node Magnetic Resonance Imaging Iron Oxide Particle Diagnostic Odds Ratio Urinary Bladder Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Anzai, Y., Blackwell, K.E., Hirschowitz, S.L., Rogers, J.W., Sato, Y., Yuh, W.T., et al. 1994. Initial clinical experience with dextran-coated superparamagnetic iron oxide for detection of lymph node metastases in patients with head and neck cancer. Radiology 192:709–715.PubMedGoogle Scholar
  2. Anzai, Y., Piccoli, C.W., Outwater, E.K., Stanford, W., Bluemke, D.A., Nurenberg, P., et al. 2003. Evaluation of neck and body metastases to nodes with ferumoxtran 10-enhanced MRI: phase III safety and efficacy study. Radiology 228:777–788.PubMedCrossRefGoogle Scholar
  3. Bellin, M.F., Roy, C., Kinkel, K., Thoumas, D., Zaim, D. et al. 1998. Lymph node metastases: safety and effectiveness of MRI with Ultrasmall Superparamanetic Iron Oxide Particles. Initial clinical experience. Radiology 207:799–808.PubMedGoogle Scholar
  4. Deserno, W.M., Harisinghani, M.G., Taupitz, M., Jager, G.J., Witjes, J.A., Mulders, P.F., Hulsbergen van de Kaa, C.A., Kaufmann, D., and Barentsz, J.O. 2004. Urinary bladder cancer: preoperative nodal staging with ferumoxtran-10-enhanced MRI. Radiology 233:449–456.PubMedCrossRefGoogle Scholar
  5. Gerlowski, L.E., and Jain, R.K. 1986. Microvascular permeability of normal and neoplastic tissues. Microvasc Res 31:288–305.PubMedCrossRefGoogle Scholar
  6. Harisinghani, M.G., Saini, S., Hahn, P.F., Weissleder, R., and Mueller, P.R. 1998. MR imaging of lymph nodes in patients with primary abdominal and pelvic malignancies using ultrasmall superparamagnetic iron oxide (Combidex). Acad Radiol 5(Suppl 1):S167–S169.PubMedCrossRefGoogle Scholar
  7. Harisinghani, M.G., Saini, S., Weissleder, R., Hahn, P.F., Yantiss, R.K., Tempany, C., et al. 1999. MR lymphangiography using ultrasmall superparamagnetic iron oxide in patients with primary abdominal and pelvic malignancies: radiographic-pathologic correlation. AJR Am J Roentgenol 172:1347–1351.PubMedGoogle Scholar
  8. Harisinghani, M.G. and Barentsz, J.O. (co-first authors), Hahn, P.F., Deserno, W., de la Rosette, J., Saini, S., et al. 2002. MR lymphangiography for detection of minimal nodal disease in patients with prostate cancer. Acad Radiol 9(Suppl 2):S312–S313.PubMedCrossRefGoogle Scholar
  9. Harisinghani, M., Barentsz, J., Hahn, P., Deserno, W., et al. 2003. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. NEJM 348: 2491–2499.PubMedCrossRefGoogle Scholar
  10. Hoffman, H.T., Quets, J., Toshiaki, T., Funk, G.F., McCulloch, T.M., Graham, S.M., et al. 2000. Functional magnetic resonance imaging using iron oxide particles in characterizing head and neck adenopathy. Laryngoscope 110:1425–1430.PubMedCrossRefGoogle Scholar
  11. Keller, T.M., Michel, S.C., Frohlich, J., Fink, D., Caduff, R., Marincek, B., et al. 2004. USPIO-enhanced MRI for preoperative staging of gynecological pelvic tumors: preliminary results. Eur Radiol 14:937–944.PubMedCrossRefGoogle Scholar
  12. Kernstine, K.H., Stanford, W., Mullan, B.F., Rossi, N.P., Thompson, B.H., Bushnell, D.L., et al. 1999. PET, CT, and MRI with Combidex for mediastinal staging in non-small cell lung carcinoma. Ann Thorac Surg 68:1022–1028.PubMedCrossRefGoogle Scholar
  13. Koh, D.M., Brown, G., Temple, L., Raja, A., Toomey, P., Bett, N., et al. 2004. Rectal cancer: mesorectal lymph nodes at MR imaging with USPIO versus histopathologic findings–initial observations. Radiology 31:91–99.CrossRefGoogle Scholar
  14. Mack, M.G., Balzer, J.O., Straub, R., Eichler, K., and Vogl, T.J. 2002. Superparamagnetic Iron Oxide–enhanced MR Imaging of Head and Neck Lymph Nodes. Radiology 222:239–244.PubMedCrossRefGoogle Scholar
  15. Michel, S.C.A., Keller, T.M., Fröhlich, J.M., Fink, D., Caduff, R., Seifert, B., Marincek, B., and Kubik-Huch, R. 2002. Preoperative Breast Cancer Staging: MR Imaging of the Axilla with Ultrasmall Superparamagnetic Iron Oxide Enhancement. Radiology 225:527–536.PubMedCrossRefGoogle Scholar
  16. Nguyen, B.C., Stanford, W., Thompson, B.H., Rossi, N.P., Kernstine, K.H., Kern, J.A., et al. 1999. Multicenter clinical trial of ultrasmall superparamagnetic iron oxide in the evaluation of mediastinal lymph nodes in patients with primary lung carcinoma. J Magn Reson Imag 10:468–473.CrossRefGoogle Scholar
  17. Nishimura, H., Tanigawa, N., Hiramatsu, M., Tatsumi, Y., Matsuki, M., and Narabayashi, I. 2006. Preoperative esophageal cancer staging: magnetic resonance imaging of lymph node with ferumoxtran-10, an ultrasmall superparamagnetic iron oxide. J Am Coll Surg. 202:604–611.PubMedCrossRefGoogle Scholar
  18. Pannu, H.K., Wang, K.P., Borman, T.L., and Bluemke, D.A. 2000. MR imaging of mediastinal lymph nodes: evaluation using a superparamagnetic contrast agent. J Magn Reson Imag 12:899–904.CrossRefGoogle Scholar
  19. Rasheed, S., Guenther, T., Talbot, I., McDonald, P., Northover, J., Stirling, J., Culver, L., Glynne-Jones, R., and Padhani, A.R. 2006. USPIO -enhanced rectal cancer specimen MRI: how well does it correlate with node identification at histopathology? Colorectal Dis. 8:721–721.Google Scholar
  20. Rockall, A.G., Sohaib, S.A., Harisinghani, M.G., Babar, S.A., Singh, N., Jeyarajah, A.R., et al. 2005. Diagnostic performance of nanoparticle-enhanced magnetic resonance imaging in the diagnosis of lymph node metastases in patients with endometrial and cervical cancer. J Clin Oncol 23:2813–2821.PubMedCrossRefGoogle Scholar
  21. Sigal, R., Vogl, T., Casselman, J., Moulin, G., Veillon, F., Hermans, R., et al. 2002. Lymph node metastases from head and neck squamous cell carcinoma: MR imaging with ultrasmall superparamagnetic iron oxide particles (Sinerem MR) – results of a phase-III multicenter clinical trial. Eur Radiol 12:1104–1113.PubMedCrossRefGoogle Scholar
  22. Stets, C., Brandt, S., Wallis, F., Buchmann, J., Gilbert, F.J., and Heywang-Kobrunner, S.H. 2002. Axillary lymph node metastases: a statistical analysis of various parameters in MRI with USPIO. J Magn Reson Imag 16:60–68.CrossRefGoogle Scholar
  23. Tatsumi, Y., Tanigawa, N., Nishimura, H., et al. 2006. Preoperative diagnosis of lymph node metastases in gastric cancer by magnetic resonance imaging with ferumoxtran-10. Gastric Cancer 9:120–128.PubMedCrossRefGoogle Scholar
  24. Vassallo, P., Matei, C., Heston, W.D.W., et al. 1994. AMI-227-enhanced MR Lymphography: usefulness for differentiating reactive from tumor bearing lymph nodes. Radiology 193:501–506.PubMedGoogle Scholar
  25. Weissleder, R., Elizondo, G., Wittenberg, J. et al. 1990. Ultrasmall paramagnetic iron oxide: an intravenous contrast agent for assessing lymph nodes with MR imaging. Radiology 175:494–498.PubMedGoogle Scholar
  26. Will, O., Purkayastha, S., Chan, C., Athanasiou, T., Darzi, A.W., Gedroyc, W., and Tekkis, P.P. 2006. Diagnostic precision of nanoparticle-enhanced MRI for lymph node metastases: a meta-analysis. Lancet Oncol 7(1):52–60.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Jelle O. Barentsz
  • Paris P. Tekkis

There are no affiliations available

Personalised recommendations